NeurAegis has been founded to translate fundamental discoveries on the mechanisms of synaptic plasticity and neuronal survival/cell death into clinical applications. These discoveries are the results of over 30 years of research by the scientific co-founders, Michel Baudry, PhD, Dean of the Graduate College of Biomedical Sciences (Western University of Health Sciences, Pomona, CA), and graduate from Ecole Polytechnique, Paris, France (X68), and Xiaoning Bi, MD, PhD, Professor, COMP (Western University of Health Sciences, Pomona, CA), directed at understanding the roles of selective biochemical cascades in both synaptic plasticity and neuroprotection/neurodegeneration. NeurAegis has identified neuroprotection as a key focus for research and development, because of the high unmet needs and tremendous research potential in this therapeutic area. Much work has been conducted to identify the mechanisms underlying neuronal death and significant progress has been made over the last 10-20 years. Nevertheless, there is still no drug on the market that provides any significant degree of neuroprotection, especially within the crucial minutes to maximum of several hours following any brain insult that results in neuronal loss.
NeurAegis has identified new molecules that provide an unprecedented level of neuroprotection in several pre-clinical models of human neurodegenerative disorders. In particular, the prototype of the company's neuroprotective drug, NA101, has been shown to protect retinal ganglion cells and vision when administered 2 h after an acute insult. NA101 has also been found to be extremely efficacious to decrease brain lesion and neuronal loss when administered 1 h after an acute severe traumatic brain injury.